Pharma News

Abbvie announced its financial results for the third quarter ended September 30, 2024, with net income of $1.56 billion, equivalent to $0.88 per diluted share. Net income was down 12 percent from $1.77 billion, or $1 per diluted share, in the same period

The Eli Lilly Company and its partners recently announced positive results from the Trailblazers -ALZ 6 study, a Phase 3b clinical trial evaluating donanemab in patients with early symptomatic Alzheimer's disease (AD).

The Ministry of Health and Welfare (MHW) recently announced an implementation plan to improve the compensation price system for innovative new drugs, which aims to revise the current regulations on drug compensation and price setting. The proposal is curr

In preclinical studies, CMG1A46 has shown rapid and profound B-cell depletion in both blood and tissue, which could lead to a more sustained patient response. The treatment is currently in phase I clinical trials in the United States and China for lymphom

AbbVie announced on Monday that it would buy Aliada Therapeutics for $1.4 billion in cash, a bet on an experimental Alzheimer's treatment that is in early development. The acquisition pitted AbbVie, which has a market capitalization of as much as $330 bil

Straumann (STMN.S), one of Switzerland's leading dental implant makers, reported impressive results on Tuesday. The report shows that the company delivered significant organic revenue growth in the third quarter, with double-digit growth rates, as more pe

Novartis, the Swiss pharmaceutical giant, announced on Tuesday that it had raised its 2024 earnings forecast for the third time. This adjustment was mainly due to the strong performance of its prescription drug line, particularly the continu

Shionogi & Co., one of Japan's leading drugmakers, said in a statement Tuesday that the results of an ongoing late-stage global clinical trial showed that its oral pill treatment for COVID-19 was significantly effective in reducing the spread of the virus

Through the implementation of the high-tech drug production strategy, Vietnamese companies are committed to ensuring a stable drug supply in the domestic market and actively preparing for integration into the global supply chain system.

Johnson & Johnson (JNJ) and Eli Lilly (LLY), two pharmaceutical giants, are expected to get new data on their key drugs in the highly competitive dermatology market. Johnson & Johnson evaluated the use of its drug Tremfya in patients with moderate plaque

While Merck & Co. 's infant respiratory syncytial virus (RSV) antibody clesrovimab is nearing approval, sanofi also won approval last year for its RSV prevention drug beyforts in partnership with astrazeneca. This news undoubtedly brings new hope to the g

A Beigene executive is under investigation by Chinese authorities, according to several local media reports.

The coming month will be a critical juncture, as growth in contract services is expected to accelerate through 2025, according to the latest research from 280 pharmaceutical companies.

French pharmaceutical giant Sanofi reported its third-quarter financial results on Friday, showing profit growth that beat analysts' expectations. The increase was mainly due to a boost in seasonal vaccine sales.

Recently, the Food and Drug Administration (F.D.A.) released information indicating that Hurricane Helen caused significant damage to a manufacturing facility in North Carolina, which further exacerbated the ongoing shortage of intravenous fluids in the U

According to the latest statistics, as of October 23, at least 12 pharmaceutical companies have published financial reports for the third quarter of 2024. In terms of net income growth, Notch Therapeutics performed particularly well, with a staggering 281

Danish pharmaceutical giant Novo Nordisk filed a formal request with the U.S. Food and Drug Administration (FDA) on Tuesday, asking the agency to ban copycats of its popular drug compounding pharmacies for weight loss and diabetes treatments. Novo Nordisk

Recently, the U.S. Food and Drug Administration (FDA) revealed that Hurricane Helen caused significant damage to an important manufacturing facility in North Carolina, further exacerbating an IV infusion shortage that has been ongoing for some time.

Sanofi is currently in "exclusive talks" with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer healthcare business Opella.

CDMO Nucleus RadioPharma, two years after completing its first round of funding, is pursuing an aggressive expansion strategy into two key regions that it believes will "significantly optimize" market access in the promising field of cancer treatment.